Alliancebernstein L.P. Corbus Pharmaceuticals Holdings, Inc. Transaction History

Alliancebernstein L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 30, 2021	SELL	$1.39 - $2.21 $60,047 - $95,472	-43,200 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$0.94 - $1.89 $42,394 - $85,239	-45,100 Reduced 51.08%	43,200 $54,000
Q3 2020 Nov 12, 2020	SELL	$1.5 - $9.38 $65,550 - $409,906	-43,700 Reduced 33.11%	88,300 $159,000
Q2 2020 Aug 13, 2020	BUY	$4.79 - $8.39 $2,395 - $4,195	500 Added 0.38%	132,000 $1.11 Million
Q1 2020 May 14, 2020	BUY	$3.44 - $7.21 $150,328 - $315,077	43,700 Added 49.77%	131,500 $689,000
Q1 2019 May 14, 2019	SELL	$5.76 - $8.95 $14,976 - $23,269	-2,600 Reduced 2.88%	87,800 $610,000
Q4 2018 Feb 13, 2019	BUY	$5.26 - $7.97 $184,100 - $278,950	35,000 Added 63.18%	90,400 $528,000
Q3 2018 Nov 08, 2018	BUY	$4.65 - $7.95 $98,115 - $167,745	21,100 Added 61.52%	55,400 $418,000
Q2 2018 Aug 13, 2018	BUY	$5.05 - $6.8 $32,825 - $44,200	6,500 Added 23.38%	34,300 $173,000
Q1 2018 May 14, 2018	BUY	$5.6 - $9.25 $70,560 - $116,550	12,600 Added 82.89%	27,800 $170,000
Q4 2017 Feb 13, 2018	BUY	$6.6 - $7.78 $27,720 - $32,676	4,200 Added 38.18%	15,200 $108,000
Q3 2017 Nov 13, 2017	BUY	$5.75 - $7.75 $63,250 - $85,250	11,000	11,000 $79,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.08B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.